OBI Pharma, Inc. was informed by the patent office that patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions And Uses Thereof has been granted by United States Patent and Trademark Office under the patent number 15/662,162. OBI-866 is an active immunotherapeutic cancer vaccine targeting SSEA-4, conjugating SSEA-4 and carrier protein KLH and triggers immune responses against hard-to-treat cancers once injected into the human system. OBI-866 has been granted by TFDA to proceed to Phase I human clinical study and is now open for enrollment actively.